Inclisiran Triumphs in Reducing LDL-C Levels in New Trial

A groundbreaking trial has confirmed that inclisiran significantly reduces low-density lipoprotein cholesterol (LDL-C) levels in patients at high and very high risk of cardiovascular events. The findings, presented at the European Society of Cardiology Congress 2025, highlight inclisiran’s effectiveness when combined with tailored lipid-lowering therapies, compared to a placebo.

The VICTORION-Difference trial was a rigorous double-blind, placebo-controlled study conducted across 133 centers in Europe. It enrolled a total of 1,770 participants who met criteria for high cardiovascular risk according to the 2019 guidelines from the European Society of Cardiology and the European Atherosclerosis Society. These patients had elevated LDL-C levels despite being treated with maximally tolerated doses of statins.

Given the established link between high LDL-C levels and the risk of atherosclerotic cardiovascular disease (ASCVD), the trial aimed to determine the impact of inclisiran on achieving LDL-C goals. Many patients on statins do not reach their target LDL-C levels, which underscores the need for additional treatment options.

Inclisiran operates through a unique mechanism as a small interfering ribonucleic acid that targets PCSK9 messenger RNA, leading to a consistent reduction in LDL-C when administered biannually after an initial dose. This trial is part of the broader VICTORION program, which has propelled inclisiran from an investigational treatment to an approved therapy with multiple indications, including its designation as a first-line treatment for ASCVD in July 2025.

Study Design and Key Findings

The primary goal of the VICTORION-Difference trial was to assess the proportion of participants who achieved their individualized LDL-C targets at day 90. These targets were set at 55 mg/dl for very high-risk individuals and 70 mg/dl for those at high risk. Results indicated that a significantly greater proportion of patients receiving inclisiran met these targets, with 84.9% achieving their LDL-C goals compared to just 31% in the placebo group. This translates to an odds ratio of 12.09 (95% CI, 9.59 to 15.24; P < 0.0001). Furthermore, the study documented average LDL-C reductions from baseline to day 360, which were -59.45% for the inclisiran group and -24.31% for the placebo cohort. This represents a least mean squares mean treatment difference of 35.14% (P < 0.0001). The trial also revealed that participants on inclisiran experienced fewer muscle-related adverse events, with 11.9% reporting such symptoms compared to 19.2% in the placebo group (P < 0.0001). Additionally, improvements were observed in pain-related quality of life metrics, further underscoring inclisiran's favorable safety profile.

Implications for Clinical Practice

Professor Ulf Landmesser, MD, PhD, director of the department of cardiology, angiology, and intensive care medicine at the Deutsches Herzzentrum der Charité in Berlin, emphasized the significance of these findings. “This large study demonstrated the effectiveness of an inclisiran-based treatment strategy over current usual care in bringing patients to early and sustained LDL-C goals, with significantly fewer adverse muscle symptoms,” he stated.

The results suggest that inclisiran could offer a practical and effective treatment alternative for many patients who do not adequately respond to existing lipid-lowering therapies. As cardiovascular disease remains a leading cause of morbidity and mortality globally, advancements in treatment options like inclisiran are critical for improving patient outcomes.

The study’s findings contribute to the growing body of evidence supporting the use of inclisiran, marking a pivotal moment in the management of hypercholesterolemia in at-risk populations. With the adoption of such treatments, clinicians may enhance their ability to meet LDL-C targets, ultimately reducing the burden of cardiovascular disease.